A Phase 1/2 interventional study of Romiplostim in Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 25th largest by enrollment, is one of 2 that started in 2002, is one of 3 in phase 1/2, and was the 4th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2002, is one of 2 in phase 1/2, and was the 4th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
This study's enrollment of 16 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura, Thrombocytopenic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.
Drug: Romiplostim
Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
Also known as: AMG 531, NPLATE
Number of Participants With Adverse Events
Time frame: From first dose through 8 weeks after last dose of study drug (11 weeks)
Number of Participants With Positive Anti-Romiplostim Antibodies
The presence or development of antibodies to romiplostim and endogenous thrombopoietin was assessed using a neutralizing bioassay. Antibody analyses were conducted on study days 29 and at the end-of-study visit (day 78). The number of participants with positive antibody binding at any time during the study is reported.
Time frame: Days 29 and 78
Number of Participants Who Achieved a Targeted Therapeutic Platelet Response
Targeted therapeutic platelet response was defined as a (single) platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)
Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L From Baseline
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)
Number of Participants With Peak Platelet Counts of ≥ 100 x 10⁹ Cells/L
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: After first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22), and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 for all participants)
Number of Participants With Peak Platelet Counts of ≥ 450 x 10⁹ Cells/L
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: After first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22), and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 for all participants)
Change From Baseline to Peak Platelet Level
Platelet count data after the use of rescue medication were not included.
Time frame: Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)
Time to Peak Platelet Count
Time from the date of study drug administration (day 1, 15 or 22) to the day of peak platelet count after each dose. Platelet count data after the use of rescue medication were not included.
Time frame: From first dose of study drug to day 15 or 22, and from the second dose of study drug (day 15 or 22) to day 78
Duration Within the Targeted Therapeutic Range
Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.
Time frame: From first dose of study drug to day 15 or 22, and from the second dose of study drug (day 15 or 22) to day 78
This was a multicenter study conducted in 6 centers in France, the Netherlands, and the United Kingdom.
| Milestone | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| Started | 4 | 4 | 7 | 1 |
| Received first dose | 4 | 4 | 7 | 1 |
| Received second dose | 4 | 4 | 6 | 0 |
| Completed | 4 | 4 | 7 | 1 |
| Not completed | 0 | 0 | 0 | 0 |
| Participants | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| All adverse events | 4 | 4 | 7 | 1 |
| Serious adverse events | 0 | 0 | 3 | 1 |
| Treatment-related adverse events | 1 | 3 | 3 | 1 |
| Serious treatment-related adverse events | 0 | 0 | 1 | 1 |
| Discontinuations due to adverse events | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
The presence or development of antibodies to romiplostim and endogenous thrombopoietin was assessed using a neutralizing bioassay. Antibody analyses were conducted on study days 29 and at the end-of-study visit (day 78). The number of participants with positive antibody binding at any time during the study is reported.
| Participants | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| Anti-romiplostim antibodies | 0 | 0 | 0 | 0 |
| Anti-thrombopoietin antibodies | 0 | 0 | 0 | 0 |
Targeted therapeutic platelet response was defined as a (single) platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 1 | 4 | 4 | 0 |
| After Second Dose | 1 | 3 | 3 | — |
| After Both Doses | 1 | 3 | 3 | — |
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 2 | 4 | 5 | 1 |
| After Second Dose | 1 | 3 | 4 | — |
| After Both Doses | 1 | 3 | 3 | — |
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 1 | 3 | 3 | 1 |
| After Second Dose | 0 | 1 | 2 | — |
| After Both Doses | 0 | 1 | 1 | — |
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 0 | 0 | 1 | 1 |
| After Second Dose | 0 | 0 | 0 | — |
| After Both Doses | 0 | 0 | 0 | — |
Platelet count data after the use of rescue medication were not included.
| 10⁹ cells/L | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 38.75 ± 50.50 | 89.98 ± 34.44 | 271.3 ± 558.4 | 1033.20 ± NA |
| After Second Dose | 11.50 ± 14.51 | 46.48 ± 25.15 | 56.38 ± 35.00 | — |
Time from the date of study drug administration (day 1, 15 or 22) to the day of peak platelet count after each dose. Platelet count data after the use of rescue medication were not included.
| days | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 10.5 (8 to 11) | 9.0 (5 to 10) | 12.0 (8 to 13) | 17.0 (17 to 17) |
| After Second Dose | 13.5 (4 to 31) | 9.5 (8 to 12) | 9.0 (5 to 15) | — |
Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.
| days | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| After First Dose | 10.0 (10 to 10) | 5.5 (1 to 7) | 8.0 (5 to 15) | — |
| After Second Dose | 1.0 (1 to 1) | 2.0 (2 to 5) | 8.0 (1 to 49) | — |
Collected over From first dose through 8 weeks after last dose of study drug (11 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romiplostim 30 µg | — | 0/4 (0%) | 4/4 (100%) |
| Romiplostim 100 µg | — | 0/4 (0%) | 4/4 (100%) |
| Romiplostim 300 µg | — | 3/7 (42.9%) | 7/7 (100%) |
| Romiplostim 500 µg | — | 1/1 (100%) | 1/1 (100%) |
| Event | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| Blood lactate dehydrogenase increasedInvestigations | 0/4 | 0/4 | 0/7 | 1/1 |
| HeadacheNervous system disorders | 0/4 | 0/4 | 0/7 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/4 | 1/7 | 0/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 0/4 | 1/7 | 0/1 |
| Rectal haemorrhageGastrointestinal disorders | 0/4 | 0/4 | 1/7 | 0/1 |
| Lower respiratory tract infectionInfections and infestations | 0/4 | 0/4 | 1/7 | 0/1 |
| Event | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 0/4 | 0/7 | 1/1 |
| HeadacheNervous system disorders | 0/4 | 3/4 | 4/7 | 1/1 |
| HaematomaVascular disorders | 0/4 | 0/4 | 1/7 | 1/1 |
| PetechiaeVascular disorders | 0/4 | 2/4 | 1/7 | 1/1 |
| ContusionInjury, poisoning and procedural complications | 0/4 | 2/4 | 2/7 | 0/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/4 | 2/4 | 3/7 | 0/1 |
| FatigueGeneral disorders | 0/4 | 1/4 | 3/7 | 0/1 |
| Oedema peripheralGeneral disorders | 0/4 | 0/4 | 3/7 | 0/1 |
| Mouth haemorrhageGastrointestinal disorders | 0/4 | 0/4 | 2/7 | 0/1 |
| NasopharyngitisInfections and infestations | 0/4 | 1/4 | 2/7 | 0/1 |
All enrolled participants
| Age, Continuous(years) | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg | Total |
|---|---|---|---|---|---|
| Mean | 60.3 ± 14.9 | 37.8 ± 13.4 | 53.9 ± 20.4 | 45.0 | 50.9 ± 17.9 |
| Sex: Female, Male(Participants) | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 4 | 1 | 10 |
| Male | 1 | 2 | 3 | 0 | 6 |
| Race/Ethnicity, Customized(Participants) | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg | Total |
|---|---|---|---|---|---|
| White | 4 | 4 | 6 | 1 | 15 |
| Black | 0 | 0 | 1 | 0 | 1 |
| Platelet Count(10⁹cells/L) | Romiplostim 30 µg | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 500 µg | Total |
|---|---|---|---|---|---|
| Mean | 13.0 ± 6.10 | 16.5 ± 10.4 | 16.4 ± 7.77 | 28.8 | 16.3 ± 8.15 |
No study locations are listed for this record.
Ran from Dec 2002 to primary completion in Jul 2004, 19 months.
Results were first posted in Dec 2019, 15 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →